View Item 

Show simple item record

Leptin for type 1 diabetes: coming onto stage to be (or not?)

dc.contributor.authorOral, Elif Ariogluen_US
dc.date.accessioned2012-03-16T15:58:12Z
dc.date.available2013-04-01T14:17:23Zen_US
dc.date.issued2012-02en_US
dc.identifier.citationOral, Elif A (2012). "Leptin for type 1 diabetes: coming onto stage to be (or not?)." Pediatric Diabetes 13(1). <http://hdl.handle.net/2027.42/90267>en_US
dc.identifier.issn1399-543Xen_US
dc.identifier.issn1399-5448en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90267
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherInsulinen_US
dc.subject.otherLipotoxicityen_US
dc.subject.otherTherapeuticsen_US
dc.subject.otherGlucagonen_US
dc.subject.otherAutoimmunityen_US
dc.titleLeptin for type 1 diabetes: coming onto stage to be (or not?)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumMetabolism, Endocrine and Diabetes Division (MEND), University of Michigan, Ann Arbor, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90267/1/j.1399-5448.2011.00797.x.pdf
dc.identifier.doi10.1111/j.1399-5448.2011.00797.xen_US
dc.identifier.sourcePediatric Diabetesen_US
dc.identifier.citedreferenceOral EA, Simha V, Ruiz E et al. Leptin‐replacement therapy for lipodystrophy. N Engl J Med 2002: 346: 570 – 578.en_US
dc.identifier.citedreferenceWang MY, Chen L, Clark GO et al. Leptin therapy in insulin‐deficient type I diabetes. Proc Natl Acad Sci U S A 2010: 107: 4813 – 4819.en_US
dc.identifier.citedreferenceZhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994: 372: 425 – 432.en_US
dc.identifier.citedreferenceFriedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998: 395: 763 – 770.en_US
dc.identifier.citedreferenceBegriche K, Letteron P, Abbey‐Toby A et al. Partial leptin deficiency favors diet‐induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 2008: 294: E939 – E951.en_US
dc.identifier.citedreferenceShimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999: 401: 73 – 76.en_US
dc.identifier.citedreferenceCohen P, Miyazaki M, Socci ND et al. Role for stearoyl‐CoA desaturase‐1 in leptin‐mediated weight loss. Science 2002: 297: 240 – 243.en_US
dc.identifier.citedreferencePuigserver P, Spiegelman BM. Peroxisome proliferator‐activated receptor‐gamma coactivator 1 alpha (PGC‐1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003: 24: 78 – 90.en_US
dc.identifier.citedreferenceMinokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty‐acid oxidation by activating AMP‐activated protein kinase. Nature 2002: 415: 339 – 343.en_US
dc.identifier.citedreferenceAsilmaz E, Cohen P, Miyazaki M et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 2004: 113: 414 – 424.en_US
dc.identifier.citedreferenceCohen P, Zhao C, Cai X et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001: 108: 1113 – 1121.en_US
dc.identifier.citedreferenceLee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin‐deficient type 1 diabetes in mice. Diabetes 2011: 60: 391 – 397.en_US
dc.identifier.citedreferenceHancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 2010: 24: 1605 – 1614.en_US
dc.identifier.citedreferenceWelt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004: 351: 987 – 997.en_US
dc.identifier.citedreferenceFarooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002: 110: 1093 – 1103.en_US
dc.identifier.citedreferenceRavussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009: 17: 1736 – 1743.en_US
dc.identifier.citedreferenceUnger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003: 65: 333 – 347.en_US
dc.identifier.citedreferenceOral EA, Chan JL. Rationale for leptin‐replacement therapy for severe lipodystrophy. Endocr Pract 2010: 16: 324 – 333.en_US
dc.identifier.citedreferencePark JY, Chong AY, Cochran EK et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long‐term leptin therapy. J Clin Endocrinol Metab 2008: 93: 26 – 31.en_US
dc.identifier.citedreferenceCochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson‐Mendenhall syndrome. J Clin Endocrinol Metab 2004: 89: 1548 – 1554.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-5448.2011.00797.x.pdf
Size:
480.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.